罕见APOE错义变异V236E和R251G与阿尔茨海默病风险的关联
该研究在544384名参与者中分析APOE罕见错义变异与阿尔茨海默病(AD)风险的关联,发现APOE ε4(R251G)的比值比为0.44,APOE ε3(V236E)的比值比为0.37,均与AD风险降低相关,且携带者AD累积发病率随年龄增长更慢。
要点
- APOE ε4(R251G)与AD风险降低相关,比值比0.44(95%CI 0.33-0.59;P=4.7×10-8)。
- APOE ε3(V236E)与AD风险降低相关,比值比0.37(95%CI 0.25-0.56;P=1.9×10-6)。
- 携带上述变异的个体AD累积发病率随年龄增长较非携带者更慢。
核心结论
- R251G与ε4共遗传,可减轻ε4相关的AD风险;V236E与ε3共遗传,其保护作用得到确认;这些变异位于apoE羧基端,提示该区域在AD发病中起重要作用。
- 作者认为,这些变异带来的大幅风险降低提示应开展蛋白质化学和功能测定,以指导靶向APOE的药物开发。
研究设计与样本
- 遗传关联研究,包括病例对照、家系、人群和纵向AD相关队列。
- 阶段1为测序发现样本,纳入37409名非唯一参与者(欧洲或混合欧洲血统),其中11868例AD和11934名对照通过分析纳入标准。
- 阶段2和3在8个队列中考虑475473名参与者,其中84513例AD和代理AD以及328372名对照通过纳入标准。
- 所有数据于2015年9月至2021年11月之间检索,于2021年4月至11月之间分析。
主要发现
- 主要病例对照分析共纳入544384名参与者;312476名(57.4%)为女性,平均(标准差;范围)年龄为64.9(15.2;40-110)岁。
- APOE ε4(R251G)与AD风险降低相关,比值比0.44(95%CI 0.33-0.59;P=4.7×10-8)。
- APOE ε3(V236E)与AD风险降低相关,比值比0.37(95%CI 0.25-0.56;P=1.9×10-6)。
- 这些变异携带者的AD累积发病率随年龄增长较非携带者更慢。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The APOE ε2 and APOE ε4 alleles are the strongest protective and risk-increasing, respectively, genetic variants for late-onset Alzheimer disease (AD). However, the mechanisms linking APOE to AD-particularly the apoE protein's role in AD pathogenesis and how this is affected by APOE variants-remain poorly understood. Identifying missense variants in addition to APOE ε2 and APOE ε4 could provide critical new insights, but given the low frequency of additional missense variants, AD genetic cohorts have previously been too small to interrogate this question robustly. OBJECTIVE: To determine whether rare missense variants on APOE are associated with AD risk. DESIGN, SETTING, AND PARTICIPANTS: Association with case-control status was tested in a sequenced discovery sample (stage 1) and followed up in several microarray imputed cohorts as well as the UK Biobank whole-exome sequencing resource using a proxy-AD phenotype (stages 2 and 3). This study combined case-control, family-based, population-based, and longitudinal AD-related cohorts that recruited referred and volunteer participants. Stage 1 included 37 409 nonunique participants of European or admixed European ancestry, with 11 868 individuals with AD and 11 934 controls passing analysis inclusion criteria. In stages 2 and 3, 475 473 participants were considered across 8 cohorts, of which 84 513 individuals with AD and proxy-AD and 328 372 controls passed inclusion criteria. Selection criteria were cohort specific, and this study was performed a posteriori on individuals who were genotyped. Among the available genotypes, 76 195 were excluded. All data were retrieved between September 2015 and November 2021 and analyzed between April and November 2021. MAIN OUTCOMES AND MEASURES: In primary analyses, the AD risk associated with each missense variant was estimated, as appropriate, with either linear mixed-model regression or logistic regression. In secondary analyses, associations were estimated with age at onset using linear mixed-model regression and risk of conversion to AD using competing-risk regression. RESULTS: A total of 544 384 participants were analyzed in the primary case-control analysis; 312 476 (57.4%) were female, and the mean (SD; range) age was 64.9 (15.2; 40-110) years. Two missense variants were associated with a 2-fold to 3-fold decreased AD risk: APOE ε4 (R251G) (odds ratio, 0.44; 95% CI, 0.33-0.59; P = 4.7 × 10-8) and APOE ε3 (V236E) (odds ratio, 0.37; 95% CI, 0.25-0.56; P = 1.9 × 10-6). Additionally, the cumulative incidence of AD in carriers of these variants was found to grow more slowly with age compared with noncarriers. CONCLUSIONS AND RELEVANCE: In this genetic association study, a novel variant associated with AD was identified: R251G always coinherited with ε4 on the APOE gene, which mitigates the ε4-associated AD risk. The protective effect of the V236E variant, which is always coinherited with ε3 on the APOE gene, was also confirmed. The location of these variants confirms that the carboxyl-terminal portion of apoE plays an important role in AD pathogenesis. The large risk reductions reported here suggest that protein chemistry and functional assays of these variants should be pursued, as they have the potential to guide drug development targeting APOE.
引用
- Le Guen Y, Belloy ME, Grenier-Boley B, et al. Association of Rare APOE Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurol. 2022. PMID: 35639372. doi:10.1001/jamaneurol.2022.1166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。